MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
510.68
-8.08
-1.56%
After Hours: 513.00 +2.32 +0.45% 19:41 03/27 EDT
OPEN
515.70
PREV CLOSE
518.76
HIGH
523.34
LOW
498.03
VOLUME
487.19K
TURNOVER
--
52 WEEK HIGH
615.00
52 WEEK LOW
265.00
MARKET CAP
11.71B
P/E (TTM)
-39.7413
1D
5D
1M
3M
1Y
5Y
1D
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Strength And Updated Fair Value Estimate
Simply Wall St · 1d ago
United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?
NASDAQ · 1d ago
Stocks to watch after market on Thursday: MDGL, M, MODD
Seeking Alpha · 2d ago
Madrigal Pharmaceuticals gains amid renewed takeover speculation
Seeking Alpha · 2d ago
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
TipRanks · 2d ago
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
The Motley Fool · 3d ago
Is Madrigal Pharmaceuticals (MDGL) Still Attractive After Mixed Returns And Strong DCF Upside?
Simply Wall St · 3d ago
Worst-performing AI-linked large-cap stocks across cloud, chips, and robotics so far in 2026
Seeking Alpha · 3d ago
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.